8-K: Amarin Announces CEO Transition as Patrick Holt Resigns, Aaron Berg Appointed as Successor

Amarin Corporation plc announced the resignation of its CEO, Patrick Holt, and the appointment of Aaron Berg as the new President and CEO, effective June 4, 2024, along with a significant change in pharmacy benefit manager coverage for VASCEPA.

Summary

• Amarin Corporation plc has announced that Patrick Holt has resigned as President and CEO, effective immediately on June 3, 2024.
• Aaron Berg, previously Executive Vice President, President U.S., has been appointed as the new President and CEO, effective June 4, 2024.
• Mr. Berg has also been appointed to the company's board of directors.
• Mr. Holt will provide consulting services to Amarin until July 3, 2024, receiving compensation equal to his base salary during this period.
• A large national pharmacy benefit manager (PBM) will no longer cover VASCEPA as the exclusive icosapent ethyl product for its commercial national formularies, effective July 1, 2024.
• This PBM decision will transition VASCEPA to not covered, impacting approximately 25% of aggregate U.S. VASCEPA prescription volume.
• The PBM's decision does not affect VASCEPA coverage within Medicare Part D formularies.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the CEO transition and the significant loss of PBM coverage, which will likely impact revenue. However, the appointment of an experienced internal candidate as CEO provides some stability.

Positives

• Aaron Berg, the new CEO, has extensive experience within Amarin, having served in various roles since 2012.
• Mr. Berg has a strong background in the pharmaceutical industry, including experience at Kos Pharmaceuticals where he helped drive annual revenues approaching $1 billion.
• The company has a clear focus on delivering value for investors and maximizing the potential of VASCEPA/VAZKEPA for patients.

Negatives

• The loss of coverage by a major PBM will negatively impact approximately 25% of U.S. VASCEPA prescription volume.
• The CEO transition may create some uncertainty in the short term.

Risks

• The loss of PBM coverage could significantly reduce VASCEPA sales and revenue.
• The CEO transition could lead to changes in strategy or execution.
• The company faces ongoing risks and uncertainties related to the market for VASCEPA and its regulatory environment.

Future Outlook

The company is focused on delivering value for investors and maximizing the potential of VASCEPA/VAZKEPA for patients, but faces challenges with the loss of PBM coverage.

Management Comments

• Odysseas Kostas, MD, the Chairman of the Board, thanked Pat for his contributions and welcomed working closely with Aaron as President & CEO.
• Aaron Berg stated his focus is to find ways to deliver value for investors and to maximize the potential of VASCEPA/VAZKEPA for patients.

Industry Context

The pharmaceutical industry is highly competitive, and changes in PBM coverage can significantly impact a drug's sales and market share. This announcement highlights the importance of securing and maintaining favorable formulary positions.

Comparison to Industry Standards

• The loss of 25% of prescription volume due to a PBM decision is a significant setback, and similar situations have caused substantial revenue declines for other pharmaceutical companies.
• Companies like Teva and Mylan have faced similar challenges with generic competition and formulary changes, leading to revenue pressures.
• The appointment of an internal candidate as CEO is a common practice in the pharmaceutical industry, often seen as a way to ensure continuity and stability.

Management Changes

Stakeholder Impact

• Shareholders will likely react negatively to the loss of PBM coverage and the CEO transition.
• Employees may experience uncertainty due to the leadership change.
• Patients may face challenges accessing VASCEPA due to the change in formulary coverage.
• Suppliers and commercial partners may be affected by the potential decrease in VASCEPA sales.

Next Steps

• Amarin will negotiate a consulting agreement with Patrick Holt.
• Aaron Berg will assume his new role as President and CEO and member of the board.
• The company will need to address the impact of the PBM's decision on VASCEPA sales.

Key Dates

Keywords

Amarin, CEO, VASCEPA, VAZKEPA, pharmacy benefit manager, PBM, Aaron Berg, Patrick Holt, cardiovascular disease, prescription volume, formulary, icosapent ethyl